Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immune Therapeutics Inc (OP: IMUN )

0.0930 UNCHANGED
Last Price Updated: 12:27 PM EDT, Oct 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0930
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0930
Today's Range 0.0930 - 0.0930
52wk Range 0.0668 - 0.8750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
From Immune Therapeutics, Inc.
Via GlobeNewswire
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
From Immune Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-84.50%
-84.50%

More News

Read More
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
From Immune Therapeutics, Inc.
Via GlobeNewswire
Statera Biopharma Shares Fall After Taking Stake In Holographic Medical Imaging
Via Benzinga
Why Are Statera Biopharma Shares Surging Today
Via Benzinga
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
From Immune Therapeutics, Inc.
Via GlobeNewswire
Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction
From Immune Therapeutics, Inc.
Via GlobeNewswire
Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development
From Immune Therapeutics, Inc.
Via GlobeNewswire
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors
From Immune Therapeutics, Inc.
Via GlobeNewswire
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.